NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
16.55
+4.55 (37.92%)
At close: Mar 28, 2025 - Market closed
NTHI Employees
NeOnc Technologies Holdings had 8 employees as of December 31, 2023.
Employees
8
Change
n/a
Growth
n/a
Revenue / Employee
$10,375
Profits / Employee
-$1,487,308
Market Cap
310.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTHI News
- 1 hour ago - NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - GlobeNewsWire
- 4 days ago - NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - GlobeNewsWire
- 6 days ago - NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors - GlobeNewsWire
- 6 days ago - NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors - GlobeNewsWire
- 3 months ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 6 months ago - NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024 - GlobeNewsWire
- 8 months ago - NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate - GlobeNewsWire
- 9 months ago - NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation - GlobeNewsWire